Determining the Best Immunization Strategy for Protecting African Children Against Invasive Salmonella Disease
Author(s) -
Hyon Jin Jeon,
Gi Deok Pak,
Justin Im,
Ellis OwusuDabo,
Yaw AduSarkodie,
Amy Gassama Sow,
Abdramane Soura,
Nagla Gasmelseed,
Karen H. Keddy,
Morten Bjerregaard-Andersen,
Frank Konings,
Abraham Aseffa,
John A. Crump,
Yun Chon,
Robert F. Breiman,
Se Eun Park,
Ligia María Cruz Espinoza,
Hye Jin Seo,
Jürgen May,
Christian G. Meyer,
Jason R. Andrews,
Ursula Panzner,
Vera von Kalckreuth,
Thomas F. Wierzba,
Raphaël Rakotozandrindrainy,
Gordon Dougan,
Myron M. Levine,
Joachim Hombach,
Jérôme H. Kim,
John D. Clemens,
Stephen Baker,
Florian Marks
Publication year - 2018
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy386
Subject(s) - medicine , typhoid fever , incidence (geometry) , disease , salmonella typhi , pediatrics , salmonella , immunology , virology , biochemistry , chemistry , physics , genetics , escherichia coli , biology , bacteria , optics , gene
The World Health Organization recently prequalified a typhoid conjugate vaccine (TCV), recommending its use in persons ≥6 months to 45 years residing in typhoid fever (TF)-endemic areas. We now need to consider how TCVs can have the greatest impact in the most vulnerable populations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom